Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?

World Journal of Gastroenterology

Volumn 19, Issue 41, 2013, Pages 6947-6956

  Grasso, Alessandro ^a   Malfatti, Federica ^a   Testa, Roberto ^a  

^a IRCCS Istituto Giannina Gaslini   (Italy)

Author keywords

Chronic hepatitis C; Direct antiviral agents; Insulin resistance; Metabolic factors

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; RIBAVIRIN PLUS METFORMIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA; LIPID; METFORMIN; PEGINTERFERON; PIOGLITAZONE; SOFOSBUVIR;

ANTIVIRAL ACTIVITY; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SUSTAINED VIRAL RESPONSE; VIRAL CLEARANCE; VIRUS INFECTIVITY; VIRUS LOAD; GENE; GENETIC POLYMORPHISM; INTERLEUKIN 28B GENE; METABOLISM; REVIEW; TREATMENT RESPONSE;

CHRONIC HEPATITIS C; DIRECT ANTIVIRAL AGENTS; INSULIN RESISTANCE; METABOLIC FACTORS;

ANTIVIRAL AGENTS; CARRIER PROTEINS; COMBINED MODALITY THERAPY; ENERGY METABOLISM; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INSULIN RESISTANCE; PHARMACOGENETICS; RISK FACTORS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84887531199     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i41.6947     Document Type: Article

References (91)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/ j.1478-3231.2008.01934.x]
2. Verna EC, Brown RS. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-940 [PMID: 17164125 DOI: 10.1016/j.cld.2006.08.012]
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965 [PMID: 1158374 DOI: 10.1016/ S0140-6736(01)06102-5]
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553]
5. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676 DOI: 10.7326/0003-4819-140-5-200403020-00010]
6. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593 [PMID: 19625712 DOI: 10.1056/NEJMoa0808010]
7. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644 [PMID: 12939590 DOI: 10.1053/ jhep.2003.50350]
8. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893 [PMID: 18508296 DOI: 10.1002/hep.22319]
9. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641 [PMID: 15765399 DOI: 10.1053/j.gastro.2004.12.049]
10. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9. e18 [PMID: 20399780 DOI: 10.1053/j.gastro.2010.04.013]
11. Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1996; 91: 1480-1481 [PMID: 8678039]
12. Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. Diabetes Care 2006; 29: 1140-1149 [PMID: 16644655 DOI: 10.2337/dc05-1995]
13. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007; 166: 196-203 [PMID: 17496314 DOI: 10.1093/aje/kwm061]
14. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423 [PMID: 18164296 DOI: 10.1053/j.gastro.2007.11.010]
15. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115 [PMID: 10905593 DOI: 10.1016/S0168-8278(00)80166-X]
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/ jhep.2001.24432]
17. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008 [PMID: 15951550 DOI: 10.1136/gut.2004.050302]
18. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848 [PMID: 14988838]
19. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour JF, Helbling B, Hadengue A, Gonvers JJ, Müllhaupt B, Cerny A, Mondelli MU, Negro F, Swiss Hepatitis C Cohort Study. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-46 [PMID: 15726693 DOI: 10.1016/j.jhep.2004.09.022]
20. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy K, Liang TJ. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132: 733-744 [PMID: 17258724 DOI: 10.1053/j.gastro.2006.11.045]
21. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Crocè L, La Mura V, Moschella F, Masutti F, Torella R, Tiribelli C, Iolascon A. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007; 46: 1009-1015 [PMID: 17668875 DOI: 10.1002/hep.21782]
22. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508 [PMID: 15509521 DOI: 10.1016/S0002-9440(10)63408-6]
23. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-576 [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x]
24. Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009; 50: 697-706 [PMID: 19582803 DOI: 10.1002/hep.23031]
25. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT, Halt-C Trial Group. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458-462 [PMID: 20156586 DOI: 10.1016/j.cgh.2010.01.022]
26. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG, ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012; 61: 128-134 [PMID: 21873466 DOI: 10.1136/gut.2010.236158]
27. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-744 [PMID: 19127513 DOI: 10.1002/ hep.22703]
28. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 2012; 56: 1681-1687 [PMID: 22619107 DOI: 10.1002/ hep.25867]
29. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, McHutchison JG, Subramanian M, Millington DM, Kelley RI, Patel K. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 2012; 56: 49-56 [PMID: 22318926 DOI: 10.1002/hep.25631]
30. Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL, Neely RD, Bassendine MF. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 2010; 139: 1774-183, 1774-183 [PMID: 20682323 DOI: 10.1053/j.gastro.2010.07.047]
31. Sheridan J, Felmlee DJ, Bridge SH, Fenwick1 F, Askew B, Neely D, Crossey MME, Taylor-Robinson SD, Toms GL, Bassendine MF. Metabolic syndrome and insulin resistance are associated with maximum hepatitis C lipoviral particles in genotype 1 infection. J Hepatol 2013; 58 Suppl 1: S202 [DOI: 10.1016/S0168-8278(13)60495-X]
32. Owen DM, Huang H, Ye J, Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108 [PMID: 19751943 DOI: 10.1016/j.virol.2009.]
33. André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-6928 [PMID: 12072493 DOI: 10.1128/JVI.76.14.6919-692 8.2002]
34. Del Campo JA, Rojas Á, Romero-Gómez M. Entry of hepatitis C virus into the cell: a therapeutic target. World J Gastroenterol 2012; 18: 4481-4485 [PMID: 22969220 DOI: 10.3748/ wjg.v18.i33.4481]
35. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581]
36. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol 2001; 96: 2468-2472 [PMID: 11513192 DOI: 10.1111/ j.1572-0241.2001.04055.x]
37. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, Hamamoto N, Ishihara S, Watanabe M, Kinoshita Y. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 2005; 20: 204-208 [PMID: 15683422 DOI: 10.1111/j.1440-1746.2004.03526.x]
38. Bortoletto G, Scribano L, Realdon S, Marcolongo M, Mirandola S, Franceschini L, Bonisegna S, Noventa F, Plebani M, Martines D, Alberti A. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010; 17: 475-480 [PMID: 19878535 DOI: 10.1111/ j.1365-2893.2009.01204.x]
39. Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, Anselmo M, Menardo G. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984-990 [PMID: 19695729 DOI: 10.1016/j.jhep.2009.07.008]
40. Fattovich G, Covolo L, Pasino M, Perini E, Rossi L, Brocco G, Guido M, Cristofori C, Belotti C, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Minola E, Negro F, Donato F, Italian Hepatitis C Cohort Study Collaborative Group. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011; 31: 66-74 [PMID: 20840397 DOI: 10.1111/j.1478-3231.2010.02343.x]
41. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970-1977 [PMID: 20234345 DOI: 10.1038/ajg.2010.110]
42. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305 [PMID: 21623851 DOI: 10.1111/j.1365-2036.2011.04716.x]
43. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55: 1187-1194 [PMID: 21703195 DOI: 10.1016/ j.jhep.2011.03.010]
44. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419 [PMID: 3899825 DOI: 10.1007/BF00280883]
45. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001; 48: 81-86 [PMID: 11403106 DOI: 10.1507/endocrj.48.81]
46. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-636 [PMID: 18174459 DOI: 10.1161/ATVBAHA.107.151092]
47. Fattovich G, Baroni GS, Pasino M, Pierantonelli I, Covolo L, Ieluzzi D, Passigato N, Tonon A, Faraci MG, Guido M, Negro F. Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. Dig Liver Dis 2012; 44: 419-425 [PMID: 22277808 DOI: 10.1016/j.dld.2011.12.006]
48. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177-1186 [PMID: 16729327 DOI: 10.1002/hep.21239]
49. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969 [PMID: 19585655 DOI: 10.1002/ hep.23046]
50. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535 [PMID: 16299039 DOI: 10.1136/gut.2005.069674]
51. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC, Min AD. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-340 [PMID: 16871569 DOI: 10.1002/hep.21261]
52. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, Tsianos E. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2008; 23: 586-591 [PMID: 17498221 DOI: 10.1111/j.1440-1746.2007.04911.x]
53. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ, Virahep-C Study Group. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-863 [PMID: 20690192 DOI: 10.1002/hep.23796]
54. Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012; 57: 32-38 [PMID: 22414761 DOI: 10.1016/j.jhep.2012.02.017]
55. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-1911 [PMID: 20235331 DOI: 10.1002/hep.23592]
56. Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat 2012; 19: 332-340 [PMID: 22497812 DOI: 10.1111/ j.1365-2893.2011.01553.x]
57. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, Mc-Carthy JJ. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011; 55: 1195-1200 [PMID: 21703198 DOI: 10.1016/j.jhep.2011.03.015]
58. Petta S, Rosso C, Leung R, Abate ML, Booth D, Salomone F, Gambino R, Rizzetto M, Caviglia P, Smedile A, Grimaudo S, Cammà C, Craxì A, George J, Bugianesi E. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 311-7. e1 [PMID: 23220171 DOI: 10.1016/j.cgh.2012.11.022]
59. Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF, Romero-Gómez M. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Aliment Pharmacol Ther 2013; 37: 74-80 [PMID: 23121166 DOI: 10.1111/apt.12113]
60. Konishi I, Hiasa Y, Tokumoto Y, Abe M, Furukawa S, Toshimitsu K, Matsuura B, Onji M. Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus. Hepatol Res 2011; 41: 928-935 [PMID: 21707884 DOI: 10.1111/j.1872-034X.2011.00833.x]
61. Pattullo V, Duarte-Rojo A, Soliman W, Vargas-Vorackova F, Sockalingam S, Fantus IG, Allard J, Heathcote J. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int 2013; 33: 410-419 [PMID: 23278982 DOI: 10.1111/ liv.12041]
62. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006; 55: 585 [PMID: 16531544]
63. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R, Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708 [PMID: 19845037 DOI: 10.1002/hep.23206]
64. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-454 [PMID: 19919569 DOI: 10.1111/j.1478-3231.2009.02171.x]
65. Overbeck K, Genné D, Golay A, Negro F, Swiss Association for the Study of the Liver (SASL). Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008; 49: 295-298 [PMID: 18555553]
66. Conjeevaram H, Burant CF, McKenna B, Harsh D, Kang H, Das AK, Everett L, White D, Lok ASF. A randomized, double-blind, placebo-controlled study of ppar-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008; 48 Suppl 1: 384A
67. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012; 56: 464-473 [PMID: 22334369 DOI: 10.1002/hep.25661]
68. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19 Suppl 2: 1-26 [PMID: 22404758 DOI: 10.1111/j.1365-2893.2012.01590.x]
69. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 DOI: 10.1056/ NEJMoa0806104]
70. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303 [PMID: 20375406]
71. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716 [PMID: 20692693 DOI: 10.1016/S0140-6736(10)60934-8]
72. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
73. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
74. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa101]
75. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024 [PMID: 21916639]
76. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR, SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18. e1-5 [PMID: 22626609 DOI: 10.1053/j.gastro.2012.05.011]
77. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
78. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Lonjon-Domanec I, DeMasi R, Picchio G, Beumont M, Marcellin P. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-1480 [PMID: 22387529 DOI: 10.1136/ gutjnl-2011-300749]
79. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Serfaty L, De Backer K, Van Heeswijk R, Luo D, Picchio G, Beumont M. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468. e1; quiz e14 [PMID: 21034744]
80. Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G, Craxì A. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009; 14: 631-639 [PMID: 19704165]
81. Prati GM, Rumi MG, Aghemo A, D'Ambrosio R, De Nicola S, Olgiati L, Donato MF, Colombo M. Insulin resistance does not predict a response to pegylated interferon plus ribavirin in chronic hepatitis C patients: a sub-analysis of the MIST study. J Hepatol 2010; 52 Suppl1: S122 [DOI: 10.1016/ S0168-8278(10)60293-0]
82. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010; 59: 1694-1698 [PMID: 20861007 DOI: 10.1136/gut.2010.219089]
83. Younossi ZM, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz E, Roberts SK, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: posthoc analysis of the realize phase III study. Hepatology 2011; 54 Suppl 1: 1008A
84. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-662 [PMID: 22296568 DOI: 10.1111/j.1365-2036.2012.04992.x]
85. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
86. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107 [PMID: 23499440 DOI: 10.1016/S01406736(13)60247-0]
87. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408 [PMID: 23499158 DOI: 10.1016/S1473-3099(13)70033-1]
88. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski M, Xie W, Larsen L, Khatri L, Podsadecki T, Bernstein B. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 /-ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. J Hepatol 2013; 58 Suppl 1: S2 [DOI: 10.1016/S0168-8278(13)60005-7]
89. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol P, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Interim analysis of an interferon (IFN)-and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients. J Hepatol 2013; 58 Suppl 1: S573 [DOI: 10.1016/ S0168-8278(13)61422-1]
90. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, McPhee M, Hernandez D, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, AI444040 Study Group. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (gt) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatol 2013; 58 Suppl 1: S570 [DOI: 10.1016/S0168-8278(13)61416-6]
91. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58: 428-438 [PMID: 23467911 DOI: 10.1002/hep.26371]